Roivant Sciences Ltd. (NASDAQ:ROIV) Receives $17.93 Consensus Target Price from Analysts

Roivant Sciences Ltd. (NASDAQ:ROIV) has earned an average rating of “Moderate Buy” from the eight analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $17.93.

ROIV has been the topic of a number of analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. Bank of America lifted their price target on Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a report on Wednesday, September 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a report on Wednesday, November 13th.

Insider Transactions at Roivant Sciences

In related news, COO Eric Venker sold 100,000 shares of the stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $11.32, for a total transaction of $1,132,000.00. Following the completion of the transaction, the chief operating officer now owns 606,525 shares of the company’s stock, valued at approximately $6,865,863. This trade represents a 14.15 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Matthew Gline sold 1,983,257 shares of Roivant Sciences stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $11.79, for a total transaction of $23,382,600.03. Following the completion of the sale, the chief executive officer now owns 17,870,543 shares of the company’s stock, valued at $210,693,701.97. This trade represents a 9.99 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 3,677,309 shares of company stock worth $43,283,184. 7.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Roivant Sciences

Several institutional investors and hedge funds have recently modified their holdings of ROIV. TOMS Capital Investment Management LP purchased a new position in Roivant Sciences in the 3rd quarter valued at approximately $46,333,000. Rubric Capital Management LP raised its stake in shares of Roivant Sciences by 15.0% in the second quarter. Rubric Capital Management LP now owns 23,000,000 shares of the company’s stock valued at $243,110,000 after acquiring an additional 3,000,000 shares in the last quarter. Troluce Capital Advisors LLC acquired a new stake in shares of Roivant Sciences in the second quarter valued at $31,182,000. FMR LLC boosted its holdings in Roivant Sciences by 5.6% in the third quarter. FMR LLC now owns 49,145,056 shares of the company’s stock valued at $567,134,000 after purchasing an additional 2,593,910 shares during the period. Finally, Geode Capital Management LLC grew its stake in Roivant Sciences by 23.2% during the 3rd quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company’s stock worth $89,400,000 after purchasing an additional 1,460,205 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Price Performance

ROIV opened at $12.11 on Monday. The firm has a market capitalization of $8.82 billion, a price-to-earnings ratio of 2.14 and a beta of 1.25. The company’s 50 day simple moving average is $11.86 and its two-hundred day simple moving average is $11.43. Roivant Sciences has a 1-year low of $9.69 and a 1-year high of $13.06.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.